FibroGen, Inc.
http://www.fibrogen.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From FibroGen, Inc.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances
Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.
After US Woes, Akebia Celebrates EU Nod For Vafseo
The US biotech is in the throes of an appeal to the FDA against the rejection of its HIF-PH inhibitor but regulators in the EU have looked more kindly on vadadustat, which will be sold as Vafseo.
Label Woes For GSK’s Jesduvroq Dampen US Anemic Kidney Disease Approval
The UK major’s Jesduvroq has become the first drug of its class to win US approval for anemic kidney disease but significant label restrictions have left some analysts lukewarm on its sales potential.
China's Shrinking Population Poses New Challenge For Pharma
For the first time in 61 years, China has reported its population is shrinking and the new demographic shift is likely to have a far-reaching impact on the pharma sector. Meanwhile, regulators have accelerated the approval of new COVID-19 drugs to relieve acute shortages.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Medical Devices
- Biomaterials
- Other Names / Subsidiaries
-
- FibroGen China Anemia Holdings Ltd.
- FibroGen (China) Medical Technology Development Co., Ltd.
- FibroGen Europe Oy
- FibroGen International (Cayman) Limited
- FibroGen International (Hong Kong) Limited
- Skin Sciences, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice